key: cord-0912041-49eyg5bx
authors: Patel, N.; Reissis, D.; Mair, M.; Hart, A.; Ragbir, M.; Giele, H.; Mosahebi, A.; Ramakrishnan, V.
title: Safety of Major Reconstructive Surgery During the Peak of the COVID-19 Pandemic in the United Kingdom and Ireland – Multicentre National Cohort Study
date: 2020-12-13
journal: J Plast Reconstr Aesthet Surg
DOI: 10.1016/j.bjps.2020.12.032
sha: 65490d718570ade97b82185d52914acb2efef236
doc_id: 912041
cord_uid: 49eyg5bx

Background:The safety of surgery during and after the COVID-19 pandemic is paramount. Early reports of excessive perioperative mortality in COVID-positive patients promoted widespread avoidance of operations. However, cancelling or delaying operations for cancer, trauma, or functional restitution has resulted in increased morbidity and mortality. Methods:A national multicentre cohort study of all major reconstructive operations carried out over a 12-week period of the ‘COVID-19 surge’ in the United Kingdom and Ireland, was performed. Primary outcome was 30-day mortality and secondary outcome measures were major complications (Clavien-Dindo grade ≥3) and COVID-19 status of patients and healthcare professionals before and after surgery. Results:418 patients underwent major reconstructive surgery with a mean operating time of 7.5 hours and 12 days’ inpatient stay. Cancer (59.8%) and trauma (29.4%) were the most common indications. COVID-19 infection was present in 4.5% of patients. 30-day post-operative mortality was 0.2%, reflecting one patient death who was COVID-negative. Overall complication rate was 20.8%. COVID-status did not correlate with major or minor complications. Eight healthcare professionals developed post-operative COVID-19 infection, seven of which occurred within the first three weeks. Conclusions: Major reconstructive operations performed during the COVID-19 crisis have been mostly urgent cases involving all surgical specialties. This cohort is a surrogate for all major operations across all surgical specialties. Patient safety and surgical outcomes have been the same as in the pre-COVID era. With adequate precautions, major reconstructive surgery is safe for patients and staff. This study helps counsel patients of COVID-19 risks in the perioperative period.

Since the World Health Organisation officially declared COVID-19 a pandemic on March 11, 2020 , healthcare systems and societies have been significantly disrupted. 1, 2 Globally, it is estimated that over 28 million (72.3%) planned operative procedures have been cancelled during the 12-week peak of the pandemic, affecting all main surgical specialties. 3 In the UK and Ireland a national directive was passed throughout the National Health Service (NHS) on March 17 to cancel all non-urgent elective operations for a period of at least three months. 4 This was primarily intended to free up hospital beds and enable operating theatres and surgical staff to be re-deployed for treating COVID-19 patients. 4, 5 However a significant side effect of this has been to deprive patients of life-changing operations, 6 causing them increased pain, morbidity, and mortality-risk, 7 with restricted function and reduced quality of life. 8 This will have a longer-term adverse impact for both individual patients and society as a whole. [8] [9] [10] Recent reports of high mortality and complication rates associated with operating on COVIDpositive patients 11, 12 reinforced this national response to cancel or delay operations. Prior to the COVID-19 pandemic, 4.2 million patients were on waiting lists for NHS treatment. This has already increased significantly over the last three months 9 and is expected to reach 10 million patients by the end of 2020.

This national collaborative study recruited consecutive data from all registered reconstructive surgical centres in the UK and Ireland during the peak months of the COVID-19 pandemic, to analyse the safety and efficacy of major reconstructive operations. These operations are typically undertaken with other surgical specialties and are lengthy with a prolonged inpatient stay. The aim was to establish whether it was safe to recommence surgical practice. This would provide guidance for surgeons to better counsel their patients within the UK and Ireland as compared to previously published work. 11, 12 Methods Design A national multicentre cohort study of all major reconstructive operations carried out in the UK and Ireland over a 12-week period, from March 1, 2020 to May 23, 2020, was performed.

Major reconstructive operations were defined as microsurgical tissue transfer, major pedicled flaps, replantations, and major limb revascularisations performed for elective, cancer or emergency indications, in both adults and children. Minor reconstructive or other surgical procedures were excluded.

The study was registered and approved as a clinical audit at the lead centre -University Hospitals of Leicester NHS Trust with registration number 10596with Caldicott guardians' approval. Confirmation was obtained from a local scientific committee that ethical approval was not required.

Consultant reconstructive surgeons were contacted and allocated as principal collaborators in all 70 major reconstructive surgical centres within the UK and Ireland (Figures 1 and 2) . This included all centres listed within the British Association of Plastic and Reconstructive Surgeons (BAPRAS) directory 13 as well as centres performing major reconstructive oral and maxillo-facial surgery. Collaborators were provided with written guidance and remote support throughout the study period.

A specifically designed proforma was developed and securely distributed to collect only pertinent, routine, anonymised data with no change to clinical care pathways (Appendix 3).

This was completed and returned for each consecutive case that met inclusion criteria.

Before locking the dataset for analysis, the local principal collaborator for each hospital was asked to confirm data completeness including 30-day follow up, and that all eligible patients had been entered into the database.

Demographic variables recorded for patients included age, gender, ethnicity, co-morbidities, smoking status, and American Society of Anesthesiologists (ASA) physical status classification I-V. 14 Operative variables included diagnosis, operation, type of flap/replantation, reconstructed body part, and date. The priority level of surgery was classified according to the NHS England specialty-specific surgical priority levels 15 on the basis of recommended time intervals from presentation to surgical treatment. Duration of the operating theatre episode (arrival of the patient in the anaesthetic room until leaving theatre) was also recorded, including total surgical time (knife-to-skin to last suture) and total non-surgical time (pre-and post-surgery).

Variables regarding the intra-operative use of personal protective equipment (PPE) and perioperative COVID-19 status were also collected. This included whether patients or healthcare professionals were clinically suspected of having COVID-19 before or within 2 weeks after surgery, and if they were tested for COVID-19 by swab test, chest x-ray or CT scan.

The primary outcome was all-cause 30-day post-operative mortality for all cases included in the study, with the day of surgery defined as day 0.

The key secondary outcome measures were major complications (Clavien-Dindo grade 3), 16 and COVID-19 status before and after surgery for both patients and healthcare professionals.

Additional secondary outcomes included minor post-operative complications (Clavien-Dindo grade ≤ 2), return to theatre and length of inpatient stay. Trends in the number of operations were also mapped against time and the national incidence of COVID-related deaths, 18 throughout the 12-week study period ( Figure 3 ).

In view of the national variations of peri-operative testing during the study period, 17 patients and healthcare professionals with symptoms of COVID-19 prior to the introduction of routine antigen swab testing in each centre were diagnosed based on clinical symptoms. After the introduction of testing in each centre, patients were diagnosed primarily based on results of their swab tests. However, if a patient had classical symptoms of COVID-19 either pre-or post-operatively but had a negative test result, they were also identified as COVID-positive, to account for the high false negative rate of swab tests in use at the time. 17 

Data was interrogated according to STROBE guidelines for observational studies. 18 Continuous data were tested for distribution. Non-normally distributed data were tested using the Mann-Whitney U test. The χ2 and Fisher's exact tests were used for categorical data. The cut-off for theatre time and length of stay was defined based on receiver operating characteristic (ROC) analysis. Relative risk (RR) and 95% confidence intervals (CI) were generated using Stata for Windows version 15. P value <0.05 (two-sided) was considered statistically significant. Missing data were included in flowcharts and descriptive analyses, allowing denominators to remain consistent in calculations.

Response rate from the 70 centres performing major reconstructive surgery in the UK and Ireland was 100% ( Figure 1 ). Six centres did not perform any major reconstructive operations during the study period. The remaining 64 centres submitted a total of 467 cases, of which 418 cases met the inclusion criteria for the study. By the date of final analysis (28 June 2020) 30-day follow-up data was available for all 418 patients.

Case numbers varied between the different geographical regions of the UK and Ireland 

There was no significant gender difference in COVID-status (p=0. The most prevalent co-morbidities amongst all patients were hypertension (21.8%), diabetes (10.3%), asthma/COPD (10.3%), and cardiovascular disorders (9.6%). COVID-positive patients had a significantly higher incidence of hypertension (p=0.000), asthma/COPD (p=0.008), cardiovascular disorders (p=0.026) or cerebrovascular disease (p=0.014) ( (Figures 1 and 6 ). Of these operations, 247 (59.1%) involved microsurgical tissue transfer, 145 (34.7%) involved major pedicled flap reconstruction and 26 (6.2%) were replantation or major revascularisation cases (Table 1) .

COVID-positive patients were more likely to undergo major pedicled flap reconstruction Overall, 85% of cases were priority level 1a, 1b or 2 according to the NHS England specialty-specific surgical priority levels. 16 Of the 19 COVID-positive patients, 5 were priority level 1b (required surgery within 72 hours) and 14 were priority level 2 (required surgery within 4 weeks).

All patients underwent major operations involving resection and/or reconstruction with a mean operating theatre duration of 7.5 hours, with no significant difference between COVIDpositive (mean 436.7 minutes) and COVID-negative patients (mean 451.7 minutes) patients (p=0.457). However, COVID-positive patients had a significantly higher mean length of inpatient stay of 16.1 days compared to 11.8 days for COVID-negative patients (p=0.031) ( Figure 5 ). 

The all-cause 30-day mortality rate was 0.2% (1/418). This accounted for a single patient who was COVID-negative throughout their treatment (Table 2) . They were ASA grade IV, and underwent a 17.8 hour neurosurgical resection involving craniectomy and reconstruction with microsurgical tissue transfer. On post-operative day 4 they had a cerebrovascular accident and died on day 7 post-operatively.

Only one other death was reported, which occurred after the 30-day follow up period. This occurred on post-operative day 31 in a patient who was ASA grade III and had undergone coronary artery bypass grafting complicated by sternal dehiscence, multiple surgical debridement's, and subsequent reconstruction with a pedicled omental flap. Following discharge from hospital, the patient was re-admitted and subsequently diagnosed with COVID-19 on post-operative day 10, before they died 21 days later. They had multiple cardiac, respiratory and metabolic co-morbidities (Table 2) .

No healthcare professionals were known to be COVID-positive pre-operatively. Eight healthcare professionals were diagnosed with COVID-19 within two weeks of treating eight separate patients (Figure 7) , giving a 1.9% infection rate for healthcare professionals. One was diagnosed with antigen swab test and seven were clinically diagnosed. Five of these were involved in potentially aerosol generating procedures of the head and neck and four had not used their FFP3 (or equivalent) mask throughout the operation. Seven occurred within the first three weeks of March, prior to the introduction of PPE guidelines for healthcare professionals.

COVID-19, and associated national directives introduced during the pandemic, have caused a significant reduction in surgical activity over this 12-week peak period throughout the UK and Ireland (Figure 3 ). However, a sizeable cancer and trauma reconstructive caseload continued, providing a representative population in which to study the safety of major reconstructive surgery for consecutive patients.

The post-operative outcomes for patients nationally demonstrate the safety of major reconstructive surgery performed during the COVID-19 pandemic. These are comparable to published data from the pre-COVID era, 19, 20 including the UK national flap registry. 21 Major reconstructive surgery has been performed to a high standard, despite the multiple challenges faced throughout the healthcare sector, both inside and outside the operating theatre. These included altered theatre environments, unfamiliar theatre teams, delayed start times, increased changeover times between cases, confusion regarding testing for patients and staff, evolving PPE requirements, and both communication and technical difficulties while wearing PPE in theatre.

Furthermore, high-quality outcomes were maintained in this patient population with high incidence of factors known to be associated with increased morbidity and mortality, 22 including urgency (85.0% priority levels 1a, 1b, and 2), complexity (59.1% microsurgical tissue transfer), long duration (average duration 7.5 hours), long inpatient stay (12 days), cancer (59.8%) or trauma (29.4%) diagnosis, and raised ASA grade (81.1% ASA II-IV). This is the first report of all-cause 30-day mortality rate (0.2%) in a complete population in which the denominator is known. This stands in contrast to the 20.5% 11 and 23.8% 12 perioperative mortality risk published for COVID-positive patients only, which may be less representative of the overall population undergoing surgery during the pandemic. 23 The current studied population had a COVID-19 incidence of 4.5% (19/418), which reflects the general population incidence at the time (6.8%). 24 As a result, our data reports a lower risk prediction for all consecutive patients undergoing major reconstructive surgery during the COVID-19 pandemic. COVID-19 positive status was not associated with increased mortality or morbidity risk throughout the healthcare systems of the UK and Ireland.

The all-cause 30-day post-operative mortality rate was 0.2% (1/418), with an additional death occurring after 30-days post-operatively (0.4% overall mortality) ( Table 2) In deciding whether or not to offer appropriate surgery for patients during the COVID-19 pandemic, the potential risk of operating must be set against the known risk of not operating.

Worldwide, over 2 million (37.7%) cancer operations are estimated to have been cancelled or delayed due to the pandemic. 3 A 6-month delay in cancer surgery provision is known to cost each patient 2.19 of the life years they should have gained, 7 resulting in the population losing 59% of the resource-adjusted life years gained by hospital treatment of an equivalent number of COVID-19 patients. 7 In the UK 27.8% of excess mortality during the pandemic did not involve COVID-19 infection. 26 Moreover, prior to the pandemic, trauma accounted for over £3.5 billion annual lost economic activity within the UK. 27 Without timely reconstructive surgery the socioeconomic cost, functional and psychological impact of cancer, trauma, and congenital abnormalities will significantly increase throughout the population.

Complex major reconstructive operations have been performed and continue to be performed throughout the COVID-19 pandemic in the UK and Ireland. Patient safety and post-operative outcomes have been demonstrated to be equivalent to the pre-COVID era. This data may inform patient-based discussion and decision making regarding undergoing surgery during the pandemic and beyond. Number of major reconstructive surgeries performed over the 12-week study period (grey), alongside the national incidence of deaths associated with COVID-19 (black) and key time points regarding national policy changes in the UK and Ireland (red, green, blue). * Clinically diagnosed prior to swab testing protocol. 

Overcoming fragmentation of health research in Europe: lessons from COVID-19

Updated country preparedness and response status for COVID-19 as of 9

Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans

Important and urgent -next steps on NHS response to covid-19

Elective surgery in the time of COVID-19

Recovery of Surgical Services

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic

Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services

NHS Confederation. Getting the NHS back on track planning for the next phase of Covid-19

Restarting Breast Reconstruction Services -Immediate Reconstruction

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

British Association of Plastic and Reconstructive Surgeons. Find a Unit

ASA Physical Status Classification System

Clinical guide to surgical prioritisation during the coronavirus pandemic

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Interpreting a covid-19 test result

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Mortality after surgery in Europe: a 7 day cohort study

ASA class is a reliable independent predictor of medical complications and mortality following surgery

British Association of Plastic and Reconstructive Surgeons. UK National Flap Registry

Identification and characterisation of the high-risk surgical population in the United Kingdom

Can we operate our patients without fear during the period of COVID-19 infection?

Coronavirus (COVID-19) Infection Survey pilot

Outcomes of Elective Major Cancer Surgery During COVID 19 at Tata Memorial Centre: Implications for Cancer Care Policy

Analysis of death registrations not involving coronavirus (COVID-19)

Implementing trauma systems: key issues for the NHS